In an effort to support the health and wellness of its guests nationwide, Dickey’s Barbecue Pit has announced that all meats sold in every location will contain “No B.S.” (Bad Stuff) by sourcing only responsibly raised, quality meats. Starting August 15, all chicken sold will now be raised without antibiotics. This breakthrough in sustainability not only comprises the brand’s traditional slow smoked chicken breast, but also will include whole smoked chickens and chicken nuggets served in kids’ meals at select stores. To learn more, click here.
The chicken is 100% vegetarian fed and humanely raised. It is also completely hormone-free and cage-free, ensuring that Dickey’s guests are served only the highest quality poultry with no additives. This announcement accompanies other advances in sustainability by the barbecue brand including humanely handled and sustainably raised brisket as well as locally-made sausage with no nitrates, nitrites* or artificial coloring or flavors. Additionally, all of Dickey’s pork products are free from added hormones**, nitrates, nitrites* and artificial coloring and flavors.
To view the multimedia release go to:
http://www.multivu.com/players/English/7717951-dickeys-barbecue-pit-no-bad-stuff-initiative/
Significant advances toward cures for blood cancer patients, many of which were funded by The Leukemia & Lymphoma Society (LLS) over the past 65 years, are among the dramatic highlights featured in Ken Burns presents CANCER: THE EMPEROR OF ALL MALADIES, a film by Barak Goodman, to air on PBS stations nationwide from March 30-April 1. The documentary series is based on the Pulitzer Prize-winning book by Siddhartha Mukherjee, MD, The Emperor of All Maladies: A Biography of Cancer.
LLS has been a driving force behind treatment breakthroughs for patients with blood cancers, including leukemia, lymphoma and myeloma. As the world’s largest voluntary health agency dedicated to finding cures for blood cancer patients, LLS has invested more than $1billion in research to advance lifesaving treatments and cures.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7409151-lls-cancer-research-pbs-series/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today congratulated trusted Edwards partner Dr. Albert Starr on receiving the 2015 Institut de France’s Grand Prix Scientifique in a Paris awards ceremony.
The Grand Prix is one of the largest prizes for scientific accomplishment and is considered the world’s most prestigious prize for cardiovascular research. The Institut’s board awarded Starr the Grand Prix in recognition of research that led to the world’s first successful artificial mitral valve implant in 1960. In the last 55 years, millions of patients around the world have benefitted from the emergence of the field of heart valve replacement and the many technological advances that followed.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7536851-france-grand-prix-starr-edwards/
Abbott announced today that the U.S. Food and Drug Administration has approved the company’s Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people with coronary artery disease in the United States.
Absorb is the only fully dissolving stent approved for the treatment of coronary artery disease, which affects 15 million people in the United States and remains a leading cause of death worldwide, despite decades of therapeutic advances. While stents are traditionally made of metal, Abbott’s Absorb stent is made of a naturally dissolving material, similar to dissolving sutures. Absorb disappears completely in approximately three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants that restrict vessel motion for the life of the person treated.
To view the multimedia release go to:
http://www.multivu.com/players/English/7826651-abbott-fda-approval-stent/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
Leading frozen bread manufacturer and the original inventor of frozen garlic bread, Cole’s Quality Foods, Inc., innovates the frozen food category yet again with the introduction of Middles™, a stuffed bread that combines delicious, decadent, savory, salty and sweet flavors into one revolutionary snack concept.
Middles become available later this month in the freezer section at grocery, club, supermarket and convenience stores nationwide for a suggested retail price of $3.99 per 10.8-ounce box. Each box contains eight tasty bread bites.
Inspired by the much-celebrated combination of bread and cheese, Middles advances the concept by featuring the soft “middle” section of popular bakery staples, including bagel, Italian and pretzel breads. They are then stuffed with savory and sweet centers, including cheddar cheese, cream cheese, and beer cheese varieties. The result is an outrageously delicious heat-and-serve stuffed bread snack that can be made in either microwave or conventional ovens in just seven to nine minutes.
To view the multimedia release go to:
https://www.multivu.com/players/English/8139251-coles-frozen-bread-middles/
Positive strides have been made since 1995 to advance science literacy in the United States, but teachers and parents agree that more hands-on, experiential learning must be adopted in order to improve science education for future generations, according to the results of the 2015 Bayer Facts of Science Education Survey released today.
For 20 years, Bayer has issued the survey, which assesses science education in the United States and evaluates its development. Although positive strides have been made, survey results emphasize the critical need to improve science education and literacy for future generations. Teachers, for example, universally agree (99 percent) that more hands-on experiential learning in general would benefit student learning.
In response, Bayer is announcing a five-year commitment to provide 1 million hands-on science learning experiences for children by 2020, timed to the 20th anniversary of the Making Science Make Sense® program, Bayer’s company-wide initiative that advances science literacy across the United States.
To view the multimedia release go to:
http://www.multivu.com/players/English/7452954-bayer-children-science-education/
Going on the offensive against one of the most daunting challenges in cancer, The Leukemia & Lymphoma Society (LLS) today announced the launch of a groundbreaking, collaborative clinical trial for acute myeloid leukemia (AML), a deadly disease which has seen few improvements in treatments in more than 40 years.
Beat AML was announced yesterday by Vice President Biden, along with many new, Moonshot inspired initiatives across industry, non-profit and government.
AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more than 10,000 deaths each year. Despite advances in treating other blood cancers, the standard of treatment for AML – a combination of toxic chemotherapies – has remained the same for more than 40 years. Overall prognosis remains poor, with a five-year survival rate below 20 percent for patients over age 60.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554854-lls-beat-aml-acute-myeloid-leukemia/
Combining their expertise in clinical trials support and cellular therapies, BloodCenter of Wisconsin (BCW) and the San Diego Blood Bank (SDBB) have created a strategic partnership to accelerate advancements in research and patient care. Together, BloodCenter of Wisconsin and San Diego Blood Bank will offer Celluvative™ – a portfolio of products and clinical trial services that will include esoteric laboratory testing, blood products for research and manufacturing applications, cell processing, and access to a broad database of diverse donors who have expressed interest in clinical trials.
“Through the strength of our partnership, we are able to offer end-to-end services to academic organizations, research institutions and other industry partners who are working to develop novel cellular therapy approaches,” said Matthew Anderson, M.D., Ph.D., medical director, BloodCenter of Wisconsin Diagnostic Laboratories. “Among other offerings, our Celluvative portfolio enables access to an extremely diverse donor database – an invaluable resource to enable advances in the area of regenerative medicine and drug discovery.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7855451-bloodcenter-sdbb-celluvative/
Nearly five dozen 2019 models meet stricter criteria to qualify for a 2019 TOP SAFETY PICK+ or TOP SAFETY PICK award from the Insurance Institute for Highway Safety. The 30 first-tier “plus” award winners earn the highest rating for passenger-side protection in a small overlap front crash and have good-rated available headlights, while the 27 winners of the second-tier award qualify with an acceptable or higher rating in the newest IIHS crash test and the nighttime headlight evaluation.
All 57 vehicles in this elite group earn good ratings in the Institute’s five other crashworthiness evaluations and have an available automatic emergency braking system that rates advanced or superior for front crash prevention.
IIHS now requires a good rating in the passenger-side small overlap front test to earn a 2019 TOP SAFETY PICK+ versus an acceptable or good rating for the 2018 award. An acceptable or good rating in the passenger-side test is a new criterion to earn a 2019 TOP SAFETY PICK.
This marks the sixth time that IIHS has raised the bar to earn the TOP SAFETY PICK+ award since introducing it in the 2013 model year to recognize vehicles that offer a superior level of safety. The TOP SAFETY PICK accolade launched in the 2006 model year to help consumers identify vehicles with the highest ratings. Over the years, IIHS has added to and strengthened criteria for both awards to encourage manufacturers to speed up safety advances.
Swissquote Bank Ltd., Switzerland’s leading online bank, announces the launch of a set of investor tools that help anticipate the impact of the French presidential election on financial markets. A key element is the Social Media Opinion Index, created in cooperation with the Social Media Lab at École polytechnique fédérale de Lausanne (EPFL).
The Index makes use of the latest advances in artificial intelligence to collect and analyze opinions about the candidates in the French election as expressed on social media networks; it allows investors to take the pulse of public online opinion about the candidates, indicating potential outcomes of the elections in real-time.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8083151-french-election-swissquote-epfl-investors/
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
